| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Huiyang Wang, Yueyang Liu, Zhenkun Guo, Minghui Cui, Peng Pang, Jingyu Yang, Chunfu W. Enhancement of oligodendrocyte autophagy alleviates white matter injury and cognitive impairment induced by chronic cerebral hypoperfusion in rats. Acta pharmaceutica Sinica. B. vol 13. issue 5. 2023-05-30. PMID:37250159. |
by the 14th day, abnormal accumulation of autophagy substrate, lysosomal dysfunction, and the activation of mechanistic target of rapamycin (mtor) pathway were observed in wm, paralleled with mature oligodendrocyte death. |
2023-05-30 |
2023-08-14 |
rat |
| Ya-Li Wang, Jian Liu, Lei Wan, Li-Ping Ruan, Wen-Fang Y. [Effect of Xinfeng Capsule on Beclin1/PI3K-AKT-mTOR of Adjuvant Arthritis Rats]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. vol 37. issue 4. 2019-02-21. PMID:30650507. |
compared with the wm group,bw, il-4, mrna expressions of atg5 and atg12, protein expressions of pi3k and mtor increased in the cm group (p <0.01 , p <0. |
2019-02-21 |
2023-08-13 |
rat |
| Irene M Ghobrial, Thomas E Witzig, Morie Gertz, Betsy LaPlant, Suzanne Hayman, John Camoriano, Martha Lacy, P Leif Bergsagel, Stacey Chuma, Daniel DeAngelo, Steven P Treo. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. American journal of hematology. vol 89. issue 3. 2014-06-04. PMID:24716234. |
everolimus is an oral raptor mtor inhibitor and has shown activity in patients with waldenstrom's macroglobulinemia (wm). |
2014-06-04 |
2023-08-13 |
Not clear |
| A Sacco, I M Ghobrial, A M Roccar. Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia. Current cancer drug targets. vol 11. issue 9. 2012-08-16. PMID:21933107. |
indeed, anti-angiogenic drugs, such as proteasome-, proteins kinase-c (pkc)-, phosphatidylinositol 3-kinase/mammalian target of rapamycin (mtor)-, and histone deacetylase (hdac)- inhibitors are now available, playing a key role in the treatment of wm both in the preclinical settings and as part of clinical trials. |
2012-08-16 |
2023-08-12 |
Not clear |
| Anas Younes, Nousheen Sama. Utility of mTOR inhibition in hematologic malignancies. The oncologist. vol 16. issue 6. 2011-10-20. PMID:21632450. |
in particular, persistent activation of mtor signaling has been identified in cell lines and patient samples with leukemias, hodgkin's lymphoma (hl), non-hodgkin's lymphoma (nhl), multiple myeloma (mm), and waldenström's macroglobulinemia (wm). |
2011-10-20 |
2023-08-12 |
Not clear |
| Anas Younes, Nousheen Sama. Utility of mTOR inhibition in hematologic malignancies. The oncologist. vol 16. issue 6. 2011-10-20. PMID:21632450. |
thus far, promising results have been seen with the application of mtor inhibitors as single agents in patients with relapsed or refractory leukemia, hl, nhl, mm, and wm. |
2011-10-20 |
2023-08-12 |
Not clear |
| Antonio Sacco, Aldo Roccaro, Irene M Ghobria. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget. vol 1. issue 7. 2011-06-07. PMID:21317453. |
we demonstrated that dual targeting of the pi3k and mtor pathways by the novel inhibitor nvp-bez235, exhibited toxicity on wm cells by directly targeting the tumor clone and indirectly through an effect on the bone marrow milieu. |
2011-06-07 |
2023-08-12 |
Not clear |
| Antonio Sacco, Aldo Roccaro, Irene M Ghobria. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget. vol 1. issue 7. 2011-06-07. PMID:21317453. |
therefore, it is critical to examine therapeutic agents that explicitly target both the pi3k/akt and mtor signaling cascades in diseases, such as waldenstrom macroglobulinemia (wm), that harbor activation of the pi3k/akt pathway. |
2011-06-07 |
2023-08-12 |
Not clear |
| Antonio Sacco, Aldo Roccaro, Irene M Ghobria. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget. vol 1. issue 7. 2011-06-07. PMID:21317453. |
these findings suggest that dual targeting of the pi3k and mtor pathways is a better modality of targeted therapy for tumors that harbor activation of the pi3k/mtor pathways, such as in wm. |
2011-06-07 |
2023-08-12 |
Not clear |
| Aldo M Roccaro, Antonio Sacco, Emanuel N Husu, Costas Pitsillides, Steven Vesole, Abdel Kareem Azab, Feda Azab, Molly Melhem, Hai T Ngo, Phong Quang, Patricia Maiso, Judith Runnels, Mei-Chih Liang, Kwok-Kin Wong, Charles Lin, Irene M Ghobria. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. vol 115. issue 3. 2010-02-23. PMID:19965685. |
we illustrated that dual targeting of the pi3k/mtor pathway by the novel inhibitor nvp-bez235 showed higher cytotoxicity on wm cells compared with inhibition of the pi3k or mtor pathways alone. |
2010-02-23 |
2023-08-12 |
Not clear |
| Aldo M Roccaro, Antonio Sacco, Emanuel N Husu, Costas Pitsillides, Steven Vesole, Abdel Kareem Azab, Feda Azab, Molly Melhem, Hai T Ngo, Phong Quang, Patricia Maiso, Judith Runnels, Mei-Chih Liang, Kwok-Kin Wong, Charles Lin, Irene M Ghobria. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. vol 115. issue 3. 2010-02-23. PMID:19965685. |
we have previously shown clinical activity of a mammalian target of rapamycin (mtor) complex 1 inhibitor in waldenstrom macroglobulinemia (wm). |
2010-02-23 |
2023-08-12 |
Not clear |
| Aldo M Roccaro, Antonio Sacco, Emanuel N Husu, Costas Pitsillides, Steven Vesole, Abdel Kareem Azab, Feda Azab, Molly Melhem, Hai T Ngo, Phong Quang, Patricia Maiso, Judith Runnels, Mei-Chih Liang, Kwok-Kin Wong, Charles Lin, Irene M Ghobria. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood. vol 115. issue 3. 2010-02-23. PMID:19965685. |
we first demonstrated that primary wm cells show constitutive activation of the pi3k/akt pathway, supported by decreased expression of phosphate and tensin homolog tumor suppressor gene (pten) at the gene and protein levels, together with constitutive activation of akt and mtor. |
2010-02-23 |
2023-08-12 |
Not clear |
| Nicholas Burwick, Aldo M Roccaro, Xavier Leleu, Irene M Ghobria. Targeted therapies in Waldenström macroglobulinemia. Current opinion in investigational drugs (London, England : 2000). vol 9. issue 6. 2008-08-28. PMID:18516762. |
several new targeted therapies have been tested preclinically in wm, with diffuse molecular targets, including the ubiquitin-proteasome pathway, pi3-kinase/akt and mtor signaling pathways, as well as the bm microenvironment. |
2008-08-28 |
2023-08-12 |
Not clear |